Half-year Report

AI SummaryClose X

Verici Dx plc reported its unaudited interim results for the six months ended June 30, 2025, showing revenue of $1.9 million, including $1.16 million from Tutivia™ testing revenues and $0.75 million from Thermo Fisher licensing revenues. The EBITDA loss was $2.8 million, and the net cash outflow from operating activities was $3.5 million. The company's cash balance as of June 30, 2025, was $0.5 million, increasing to approximately $5.3 million by September 30, 2025. Post period end, Verici Dx raised £6.35 million (gross) to support revenue scaling, extending the cash runway into the second half of 2026. 591 Tutivia™ tests were ordered in H1 2025.

Disclaimer*

Companies

Verici DX (VRCI)
UK 100

Latest directors dealings